Table 2.
Clinical information of HIV-infected participants attending two selected ART clinics in Kano from June 2015 to May 2016 (n = 1521).
| Variables | Number (%) |
|---|---|
| ART status | |
| ART | 1288 (84.7) |
| Non-ART | 233 (15.3) |
| ART start year | |
| 2005 | 54 (3.6) |
| 2006 | 34 (2.2) |
| 2007 | 130 (8.5) |
| 2008 | 156 (10.3) |
| 2009 | 155 (10.2) |
| 2010 | 112 (7.4) |
| 2011 | 82 (5.4) |
| 2012 | 106 (7.0) |
| 2013 | 165 (10.8) |
| 2014 | 178 (11.7) |
| 2015 | 349 (23.0) |
| ART regimen (n = 1288) | |
| TDF/3TC/EFV | 529 (41.1) |
| AZT/3TC/NVP | 746 (57.9) |
| Others | 13 (1.0) |
| Current WHO stage | |
| Stage I | 348 (22.9) |
| Stage II | 680 (44.7) |
| Stage II | 313 (20.6) |
| Stage IV | 180 (11.8) |
| Daily dose of cotrimoxazole | |
| No | 749 (49.2) |
| Yes | 772 (50.8) |
ART: antiretroviral therapy; AZT: zidovudine; EFV: efavirenz; NVP: nevirapine; 3TC: lamivudine; WHO: World Health Organization.